The linear gadolinium-based contrast agent (GBCA) gadodiamide accumulates in the brain early in the course of multiple sclerosis (MS), but has no apparent clinical or radiologic impact, results of a longitudinal study suggest.
“Patients with more frequent us…
Read More
Reserve Gadolinium for MS Diagnosis Only? – Medscape
Published
Global News 